Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Ovary Cancer: early-phase trial registry

6 of 11 indexed Ovary Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 6 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Ovary Cancer: 11 US clinical trials tracked, 6 recruiting.

Ovary Cancer is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Northwestern University, running 2 of these trials.

Enrollment posture brief

Registry condition ovary-cancer

OPEN 6 | RECR 55% | LATE 0 | EARLY 5 | RANK #1577 | SPON 2

Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)

Acute Pancreatitis81.8%Ovary Cancer (this)55%Acute Stroke45.5%Acquired Brain Injury36.4%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Ovary Cancer

Ovary Cancer lists 6 open slots (55% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Ovary Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Ovary Cancer is recruiting above its size-band peers.

    6 of 11 indexed trials (54.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Ovary Cancer research.

    Northwestern University accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Ovary Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 30 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.

  4. Ovary Cancer research is mostly interventional.

    10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23

Open and recent trials

11 total, page 1 of 1

RECRUITING NA 192 participants

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

Northwestern University

NCT05743517

RECRUITING Phase 2 53 participants

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

University of Colorado, Denver

NCT05887609

RECRUITING NA 30 participants

Multimedia Aid for Genetic Testing in Gynecologic Oncology

UNC Lineberger Comprehensive Cancer Center

NCT07084168

RECRUITING NA 30 participants

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy

Northwestern University

NCT05990426

RECRUITING Phase 2 18 participants

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06617923

RECRUITING 10 participants

Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study

University of Tennessee Graduate School of Medicine

NCT06800105

ACTIVE NOT RECRUITING NA 603 participants

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health

University of Alabama at Birmingham

NCT04000880

ACTIVE NOT RECRUITING NA 205 participants

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

M.D. Anderson Cancer Center

NCT05677048

ACTIVE NOT RECRUITING Phase 1 137 participants

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

ENB Therapeutics

NCT04205227

COMPLETED Phase 1 23 participants

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Novita Pharmaceuticals

NCT03199586

COMPLETED Phase 2 5 participants

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Seagen

NCT03245736

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3

Named interventions

Most-linked intervention names on Ovary Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Tisotumab Vedotin Drug
1 trials
NP-G2-044 Drug
1 trials
Combined Diet and Exercise Other
1 trials
Exercise-Diet Other
1 trials
Diet-Exercise Other
1 trials
Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health Behavioral
1 trials
IGNITE-TX and free genetic testing and counseling group Behavioral
1 trials
IGNITE-TX Group Behavioral
1 trials

US sites by state

Facility locations filed on Ovary Cancer trials. A trial with sites in several states counts in each.

Illinois 3 trials
Texas 2 trials
Tennessee 2 trials
Pennsylvania 2 trials
California 2 trials
Wisconsin 1 trials
New York 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Ovary Cancer page

11 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ovary Cancer condition card totals 11 registered trials; most-linked intervention Tisotumab Vedotin; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.